Newborn Genomic Screening Goes National — A 2026 Coverage and Workflow Guide
Short answer: A $14.4 million NIH-funded pilot called BEACONS has begun sequencing up to 30,000 newborns' genomes across 10 states to test whether whole-genome sequencing belongs in state newborn screening programs, while a separate bipartisan bill, H.R. 7118, would clarify Medicaid coverage for diagnostic sequencing in children. These are two different tracks with two different payers, and neither one means your lab's genomic newborn test is reimbursable yet.
A national pilot, not a national program
On October 1, 2025, a consortium led by Mass General Brigham and Ariadne Labs began enrolling newborns in BEACONS (Building Evidence and Collaboration for GenOmics in Nationwide Newborn Screening), funded by a $14.4 million award from the NIH Common Fund Venture Program. The three-year study will enroll up to 30,000 newborns across as many as 10 states, with co-investigators at Boston Children's Hospital, Albert Einstein College of Medicine, Case Western Reserve University, and Baylor College of Medicine, alongside the Association of Public Health Laboratories and Illumina as a sequencing partner.
The goal is narrower than the headlines suggest: BEACONS is testing whether whole-genome sequencing can be integrated into existing state public health newborn screening infrastructure — the same heel-stick system that already screens roughly 3.6 million U.S. babies a year — not launching a new commercial or Medicaid benefit. Which specific conditions will be screened is still being decided, with input from state public health labs and rare disease advocates.
That distinction matters for anyone in revenue cycle: a state-run, NIH-funded research pilot does not generate a payer claim the way a clinical diagnostic order does. Families enrolled in BEACONS are not being billed, and their insurers are not being asked to adjudicate a CPT code. If your lab is fielding questions from clinicians who saw the BEACONS coverage and assume genomic newborn screening is now a covered benefit, the honest answer is: not this pathway, not yet.
The evidence BEACONS is building on
BEACONS isn't the first U.S. attempt at genomic newborn screening — it's an attempt to take earlier pilots to public-health scale. Columbia University Irving Medical Center's GUARDIAN study sequenced an initial cohort of 4,000 newborns between September 2022 and July 2023 and diagnosed 120 children with serious genetic conditions. Of those 120, standard newborn screening had caught only 10. The overall positive rate was 3.7%, or 0.6% when G6PD deficiency cases are excluded — roughly double the 0.3% detection rate New York State's conventional screening achieves. GUARDIAN's panel has since grown from an initial 156 treatable conditions to more than 450, with new conditions added most years.
The Recommended Uniform Screening Panel itself isn't static, either. On December 16, 2025, HHS Secretary Robert F. Kennedy Jr. added Duchenne muscular dystrophy and metachromatic leukodystrophy to the RUSP, citing HRSA's finding that most children with these conditions aren't diagnosed until age 4 or 5 — well after irreversible disease progression and after the window for FDA-approved early-intervention therapies has narrowed. It's the kind of addition genomic screening advocates point to as the case for sequencing: a diagnosis available at birth instead of after years of a diagnostic odyssey.
The coverage question runs on a separate, slower track
If BEACONS is the screening story, H.R. 7118, the Genomic Answers for Children's Health Act of 2026, is the billing story — and it's further from resolved. Introduced in January 2026 by a bipartisan group of 16 representatives led by Rep. Scott Peters (D-CA) and Rep. Gus Bilirakis (R-FL), the bill would amend the Social Security Act to clarify that whole-genome and whole-exome sequencing are covered diagnostic tools for children under Medicaid's Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit, and would direct states to add a diagnosis-related-group payment to support sequencing access in inpatient settings. As of this writing it has been referred to the House Committee on Energy and Commerce and has not been marked up or scheduled for a floor vote.
That gap — between "a pilot is sequencing newborns" and "Medicaid will reliably pay for it" — is exactly where labs get burned. Some state Medicaid programs already reimburse rapid whole-genome sequencing today, but only in a specific lane: critically ill infants in the NICU or PICU, billed under 81425, 81426, or 81427, under medical-necessity criteria that require acute illness of suspected genetic origin — not population-level newborn screening. California's Medi-Cal and Florida's Medicaid managed-care plans are examples of state programs with published rWGS billing guidance along these lines. H.R. 7118 would broaden that Medicaid pathway; BEACONS doesn't touch it at all, because BEACONS isn't billing anyone.
What this means for your lab this quarter
None of this should sit on a shelf until it resolves. A few concrete steps are worth taking now:
Track BEACONS enrollment by state, not as a national rollout. If your lab operates in one of the up-to-10 participating states, expect clinician and patient questions about how a BEACONS result differs from a clinical diagnostic order — and make sure front-line staff can explain that BEACONS results don't flow through the same consent, billing, or reporting pathway as a test your lab performs and bills directly.
Keep rapid WGS medical-necessity criteria current. Where state Medicaid programs already reimburse 81425–81427 for critically ill infants, payer criteria are narrow and specific — acute presentation, suspected genetic etiology, NICU/PICU setting. Confirm current requirements with the relevant state Medicaid program or MAC rather than assuming last year's criteria still apply; our companion guide to Medicare coverage of genetic testing walks through how documentation requirements typically get verified.
Watch H.R. 7118's committee status, not just headlines about it. A bill referred to committee in January 2026 can sit for a full session or move quickly if attached to a larger vehicle; either way, "a bill was introduced" is not the same claim as "Medicaid now covers this," and billing on that assumption is a fast way to generate denials. If your lab already fields WGS/WES orders for pediatric patients, our guide to prior authorization for genetic testing covers how to document medical necessity while coverage policy is still catching up to the science.
Finally, don't let "the RUSP just grew" and "BEACONS is sequencing newborns" collapse into a single narrative internally. One is an incremental, HHS-approved addition to an established public health program; the other is a research pilot testing whether a much larger genomic approach belongs in that program at all. Ordering clinicians, genetic counselors, and RCM teams all benefit from keeping that line clear when a family asks what their newborn's result actually means — and who, if anyone, is being billed for it.
Frequently asked questions
Is BEACONS available at every hospital, or only in certain states?
BEACONS is enrolling in up to 10 states as part of a three-year NIH-funded pilot that began October 1, 2025. It is not a nationwide clinical service, and which specific states and conditions are included is still being finalized by the consortium with input from state public health labs.
Will families or insurers be billed for a BEACONS genomic screen?
No. BEACONS is a research study funded by a $14.4 million NIH Common Fund award, not a clinical service submitted to payers. Distinguish it clearly from diagnostic whole-genome sequencing your lab bills directly, which follows separate payer rules entirely.
Does H.R. 7118 mean Medicaid covers whole genome sequencing for children now?
Not yet. The bill was introduced in January 2026 and referred to the House Energy and Commerce Committee; it has not passed. Some state Medicaid programs already cover rapid WGS for critically ill infants under narrower, existing criteria — that coverage predates and is separate from H.R. 7118.
What CPT codes apply to whole genome sequencing in the NICU today?
Rapid and standard whole-genome and exome sequencing generally bill under 81425, 81426, and 81427. Coverage and medical-necessity criteria vary by state Medicaid program and by MAC, so confirm current requirements before submitting rather than assuming uniform national policy.
Should our lab build out a genomic newborn screening test menu now?
Not on the assumption of imminent broad reimbursement. The evidence base (GUARDIAN, BabySeq) and the funded infrastructure (BEACONS) are advancing faster than payer policy. Labs are better served tracking state RUSP and Medicaid decisions closely than assuming national coverage is close.
Educational disclaimer: This article summarizes publicly available information about federal research funding, newborn screening policy, and pending legislation as of September 2026 for the education of laboratory, clinical, and revenue-cycle professionals. It is not legal, billing, or coverage advice, and it does not represent a determination by any payer. Medicaid coverage varies by state and changes over time; confirm current criteria with the applicable state Medicaid program, MAC, or payer before billing. For broader context on how genetic testing intersects with coverage policy, visit ScreenMyGene.
Sources: Mass General Brigham/GeneDx, "First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award" (2026); Health Resources and Services Administration, Recommended Uniform Screening Panel; HHS press release, "Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy to Newborn Screenings" (Dec. 16, 2025); Columbia University Irving Medical Center, "In Pioneering Study, Gene Technology Outperforms Standard Newborn Screening Tests" (GUARDIAN study); Congress.gov / LegiScan, H.R. 7118, Genomic Answers for Children's Health Act of 2026 (119th Congress); Maryland Department of Health, Whole Genome Sequencing (WGS) Clinical Criteria (CPT 81425, 81426, 81427).